期刊文献+

黄芩苷对肺炎衣原体感染小鼠血清sICAM-1、sVCAM-1及E选择素的调节作用 被引量:4

The Influence of Baicalin on the Level of Serum sICAM-1,sVCAM-1 and sE-slectin in CPn-Infected Mice
下载PDF
导出
摘要 目的探讨肺炎衣原体(CPn)感染高脂饮食小鼠后血清细胞间黏附分子-1(sICAM-1)、血管细胞黏附分子-1(sVCAM-1)、E选择素(sE-slectin)的变化及黄芩苷调节作用。方法将50只小鼠随机分为黄芩苷高剂量组、黄芩苷低剂量组、阿奇霉素组、模型组、正常对照组。除正常对照组外均于喂饲高脂饲料1周后,经一侧鼻腔吸入含CPn的培养液,每周1次,共3次。最后1次接种5d后开始给药至实验结束,第1次接种后第18周处死全部动物。结果模型组血清sICAM-1、sVCAM-1、sE-slectin均较正常对照组升高(P<0.01);与模型组比较,黄芩苷高剂量组、低剂量组和阿奇霉素组3个指标均有不同程度下降,其中黄芩苷低剂量组和阿奇霉素组sICAM-1和sE-slectin显著降低(P<0.01)。结论CPn感染高脂饮食小鼠可使血清sICAM-1、sVCAM-1、sE-slectin水平升高,黄芩苷高剂量、低剂量和阿奇霉素均具有不同程度的调节作用,从而在一定程度上抑制动脉粥样硬化的形成。 Objective To study the variation of serum slCAM- 1, sVCAM- 1 and sE - slectin in diet - induced hyperlipidemic and chronic CPn - infected mice and the intervention of haicalin. Methods Eight - week - old SPF male C57BL/6J mice were divided into 5 groups randomly: High- dosagehaicalin group (group Ⅰ ), low - dosage - haicalin group (group Ⅱ ), azithromycin group(group Ⅲ ), model group (group Ⅳ ) and normal group (group Ⅴ ). Following cholesterol- supplemented diet for one week, group Ⅰ , group Ⅱ , group Ⅲ , group Ⅳ and group Ⅴ were inoculated with CPn at (0.5 × 10^7 - 1.0 ×10^7) IFU per inoculation. Each mouse in these groups was inoculated once a week for 3 consecutive weeks. Administration started 5 days after the last inoculation. Results The level of serum slCAM - 1, sVCAM- 1 and sE - slectin increased in group Ⅳ. All of them in three treatment groups declined at different levels. Conclusion CPn infection could raise the level of serum slCAM - 1, sVCAM- 1 and sE- slectin in di- et- induced hyperlipidemic C57BL/6J mice. Early treatment by baicalin or azithromycin could lower them in some extent.
出处 《中西医结合心脑血管病杂志》 2006年第10期874-875,共2页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
基金 国家自然科学基金资助项目(No.30070938)
关键词 肺炎衣原体 黄芩苷 细胞间黏 附分子-1 血管细胞黏附分子-1 E选择素 chlamydia pneumoniae baicalin slCAM-1 sVCAM-1 sE- slectin
  • 相关文献

参考文献9

二级参考文献27

  • 1[1]Mulvihill NT,Foley JB.Inflammation in actue coronary syndromes.Heart,2002,87: 201-204.
  • 2[2]Shimada K,Mokuno H,WatanabeY,et al. High prevalence of seropositivity for antibodies to Chlamydia-specific lipopolysaccharide in patients with acute coronary syndrome. Cardiovasc Risk,2000,7:209-13.
  • 3[3]Wang SP The microimmunofluorescence test for Chlamydia pneumoniae infection:technique and interpretation.J I nfect Dis,2000,181:S421-2.
  • 4[4]Sessa R,Pietro MD,Santino 1,et a1.Chlamydia pneumoniae infection and atherosclerotic coronarydisease.Am Heart J,1999,137:1116-19.
  • 5Chou T C, Chang L P, Li C Y, et al. The antiinflammatory and analgesic effects of baicalin in carrageenan-evoked thermal hyperalgesia [J]. Anesth Analg, 2003, 97 (6): 1724.
  • 6Rose R. Atherosclerosis-an inflammatory disease [ J]. N Engl J Med, 1999, 340: 115.
  • 7Cybulsky M I, Gimbrone Ma Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis [J].Science, 1991, 251: 788.
  • 8Saikku P, M Leinoman, K Mattila, et al. Serologic evidence of an association of a novel chlamydia, TWAR with chronic coronary heart disease and acute myocardial infarction [J]. Lancet, 1988: 983.
  • 9Kuo C C, A Shor, L A Campbell, et al. Demonstration of chlamydia pneumoniae in atherosclerotic lesions of coronary arteries [J]. J Infect Dis, 1993, 167: 841.
  • 10Belland R J, Ouellette S P, Gieffers J, et al. Chlamydia pneumoniae and atherosclerosis [J]. Cell Microbiol, 2004, 6 (2): 117.

共引文献28

同被引文献58

引证文献4

二级引证文献147

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部